Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2012-01-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Litramine in 1 Year Weight Loss Study
NCT03227276
Safety and Efficacy of Litramine in Overweight and Obese Subjects
NCT01233349
Litramine for Weight Loss
NCT02488356
Effect of Litramine on Fat Excretion
NCT01590667
Benefit and Tolerability of IQP-LU-104 in Weight Loss
NCT03888911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Identical to Litramine 2 tablets 3 times daily (oral consumption, after meal)
Placebo
Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
Litramine
Fibre complex of plant origin n tablet form 2 tablets 3 times daily (oral consumption, after meal)
Litramine
Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Litramine
Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
Placebo
Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 25-35 before initial weight loss
* Documented compliance (according to the investigator's judgement) to previous weight loss clinical trials/ regimens
Exclusion Criteria
* BMI \< 18.5
* Presence of other factor(s) that, in the investigator's judgement, should preclude subject participation
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InQpharm Group
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barbara Grube
Berlin, State of Berlin, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Grube B, Chong PW, Alt F, Uebelhack R. Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study. J Obes. 2015;2015:953138. doi: 10.1155/2015/953138. Epub 2015 Sep 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INQ/024511
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.